{"parse":{"title":"Wilson Therapeutics","pageid":43152107,"revid":827550748,"text":{"*":"<div class=\"mw-parser-output\"><table class=\"infobox vcard\" style=\"width:22em\"><caption class=\"fn org\">Wilson Therapeutics AB</caption><tbody><tr><td colspan=\"2\" class=\"logo\" style=\"text-align:center\">\n<a href=\"/wiki/File:Wilson_Therapeutics_Company_Logo.png\" class=\"image\"><img alt=\"Wilson Therapeutics Company Logo.png\" src=\"//upload.wikimedia.org/wikipedia/en/thumb/9/90/Wilson_Therapeutics_Company_Logo.png/220px-Wilson_Therapeutics_Company_Logo.png\" width=\"220\" height=\"121\" srcset=\"//upload.wikimedia.org/wikipedia/en/thumb/9/90/Wilson_Therapeutics_Company_Logo.png/330px-Wilson_Therapeutics_Company_Logo.png 1.5x, //upload.wikimedia.org/wikipedia/en/9/90/Wilson_Therapeutics_Company_Logo.png 2x\" data-file-width=\"425\" data-file-height=\"234\" /></a></td></tr><tr><th scope=\"row\" style=\"padding-right:0.5em;\"><div style=\"padding:0.1em 0;line-height:1.2em;\"><a href=\"/wiki/List_of_business_entities\" class=\"mw-redirect\" title=\"List of business entities\">Type</a></div></th><td class=\"category\" style=\"line-height:1.35em;\">\nPublic company</td></tr><tr><th scope=\"row\" style=\"padding-right:0.5em;\"><a href=\"/wiki/Ticker_symbol\" title=\"Ticker symbol\">Traded&#160;as</a></th><td style=\"line-height:1.35em;\">\nOMX: WTX</td></tr><tr><th scope=\"row\" style=\"padding-right:0.5em;\">Industry</th><td class=\"category\" style=\"line-height:1.35em;\">\nPharmaceutical industry</td></tr><tr><th scope=\"row\" style=\"padding-right:0.5em;\">Founded</th><td style=\"line-height:1.35em;\">\n2012</td></tr><tr><th scope=\"row\" style=\"padding-right:0.5em;\">Headquarters</th><td class=\"adr\" style=\"line-height:1.35em;\">\n<span class=\"locality\">Stockholm</span>, <span class=\"country-name\">Sweden</span></td></tr><tr><th scope=\"row\" style=\"padding-right:0.5em;\">Products</th><td style=\"line-height:1.35em;\">\n<a href=\"/wiki/Decuprate\" class=\"mw-redirect\" title=\"Decuprate\">Decuprate</a></td></tr><tr><th scope=\"row\" style=\"padding-right:0.5em;\">Website</th><td style=\"line-height:1.35em;\">\n<a rel=\"nofollow\" class=\"external text\" href=\"http://www.wilsontherapeutics.com\">www.wilsontherapeutics.com</a></td></tr></tbody></table>\n<p><b>Wilson Therapeutics</b> is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for rare diseases. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.\n</p><p>Wilson Therapeutics' lead product, Decuprate, is the proprietary <a href=\"/wiki/Bis-choline_tetrathiomolybdate\" title=\"Bis-choline tetrathiomolybdate\">bis-choline salt of tetrathiomolybdate</a>. Decuprate is initially being developed as a novel treatment for <a href=\"/wiki/Wilson%27s_disease\" title=\"Wilson&#39;s disease\">Wilson's disease</a>, a rare <a href=\"/wiki/Genetic_disorder\" title=\"Genetic disorder\">genetic disease</a> that affects approximately 1 in 30,000, causing copper overload in the liver, brain and other tissues and resulting in organ damage and dysfunction.<sup id=\"cite_ref-1\" class=\"reference\"><a href=\"#cite_note-1\">&#91;1&#93;</a></sup> Decuprate has been granted <a href=\"/wiki/Orphan_drug\" title=\"Orphan drug\">orphan drug</a> designation for the treatment of Wilson's disease in both Europe and the United States.<sup id=\"cite_ref-2\" class=\"reference\"><a href=\"#cite_note-2\">&#91;2&#93;</a></sup>. Wilson Therapeutics presented during the 10th Kempen &amp; Co Life Sciences Conference 2017 and showed the world the result with the drug Decuprate. The company also presented during the international investmentconference Bioequity Europe in Paris, France, on May 23rd 2017 and showed some promising result.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (May 2017)\">citation needed</span></a></i>&#93;</sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Clinical_trials\">Clinical trials</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Wilson_Therapeutics&amp;action=edit&amp;section=1\" title=\"Edit section: Clinical trials\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>As of 2016, tetrathiomolybdate had been tested in over 500 patients for up to seven years, primarily in <a href=\"/wiki/Oncology\" title=\"Oncology\">oncology</a><sup id=\"cite_ref-3\" class=\"reference\"><a href=\"#cite_note-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-4\" class=\"reference\"><a href=\"#cite_note-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-5\" class=\"reference\"><a href=\"#cite_note-5\">&#91;5&#93;</a></sup><sup id=\"cite_ref-6\" class=\"reference\"><a href=\"#cite_note-6\">&#91;6&#93;</a></sup><sup id=\"cite_ref-7\" class=\"reference\"><a href=\"#cite_note-7\">&#91;7&#93;</a></sup><sup id=\"cite_ref-8\" class=\"reference\"><a href=\"#cite_note-8\">&#91;8&#93;</a></sup><sup id=\"cite_ref-9\" class=\"reference\"><a href=\"#cite_note-9\">&#91;9&#93;</a></sup><sup id=\"cite_ref-10\" class=\"reference\"><a href=\"#cite_note-10\">&#91;10&#93;</a></sup><sup id=\"cite_ref-11\" class=\"reference\"><a href=\"#cite_note-11\">&#91;11&#93;</a></sup><sup id=\"cite_ref-12\" class=\"reference\"><a href=\"#cite_note-12\">&#91;12&#93;</a></sup> and Wilson's disease,<sup id=\"cite_ref-13\" class=\"reference\"><a href=\"#cite_note-13\">&#91;13&#93;</a></sup><sup id=\"cite_ref-14\" class=\"reference\"><a href=\"#cite_note-14\">&#91;14&#93;</a></sup><sup id=\"cite_ref-15\" class=\"reference\"><a href=\"#cite_note-15\">&#91;15&#93;</a></sup><sup id=\"cite_ref-16\" class=\"reference\"><a href=\"#cite_note-16\">&#91;16&#93;</a></sup> as well as some other clinical pathologies.<sup id=\"cite_ref-17\" class=\"reference\"><a href=\"#cite_note-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-18\" class=\"reference\"><a href=\"#cite_note-18\">&#91;18&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"History\">History</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Wilson_Therapeutics&amp;action=edit&amp;section=2\" title=\"Edit section: History\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Wilson Therapeutics was founded in 2012 by <a href=\"/wiki/HealthCap\" title=\"HealthCap\">HealthCap</a>, one of the leading European life science venture capital funds.<sup id=\"cite_ref-19\" class=\"reference\"><a href=\"#cite_note-19\">&#91;19&#93;</a></sup> In 2014, Wilson Therapeutics closed a $40 million Series B financing co-led by new investors, Abingworth LLP, MVM Life Science Partners LLP and NeoMed Management AS. HealthCap also participated in the round.<sup id=\"cite_ref-20\" class=\"reference\"><a href=\"#cite_note-20\">&#91;20&#93;</a></sup><sup id=\"cite_ref-21\" class=\"reference\"><a href=\"#cite_note-21\">&#91;21&#93;</a></sup> On April 29, 2016, Wilson Therapeutics announced its initial public offering on <a href=\"/wiki/Nasdaq_Stockholm\" class=\"mw-redirect\" title=\"Nasdaq Stockholm\">Nasdaq Stockholm</a> and had its first day of trading on May 12, 2016.<sup id=\"cite_ref-22\" class=\"reference\"><a href=\"#cite_note-22\">&#91;22&#93;</a></sup><sup id=\"cite_ref-23\" class=\"reference\"><a href=\"#cite_note-23\">&#91;23&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Wilson_Therapeutics&amp;action=edit&amp;section=3\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist columns references-column-width\" style=\"-moz-column-width: 35em; -webkit-column-width: 35em; column-width: 35em; list-style-type: decimal;\">\n<ol class=\"references\">\n<li id=\"cite_note-1\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-1\">^</a></b></span> <span class=\"reference-text\">Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. 2007. \"Wilson's disease.\" <i>Lancet</i> <b>369</b>:397-408.</span>\n</li>\n<li id=\"cite_note-2\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-2\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external autonumber\" href=\"http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=346511\">[1]</a> U.S. Food and Drug Administration Orphan Drug Designations and Approvals</span>\n</li>\n<li id=\"cite_note-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-3\">^</a></b></span> <span class=\"reference-text\">Berenson JR, Boccia RV, Bashey A, Levine AM, Koc ON, Callahan JA, Mazar AP, Reich SD, 2006. \"Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients with Advanced Hematologic Malignancies. Presentation at the Amer Soc Hematol 2006 Annual Meeting\". <i>Blood</i> <b>108</b>: Abstract 2593.</span>\n</li>\n<li id=\"cite_note-4\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-4\">^</a></b></span> <span class=\"reference-text\">Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta K, Redman BG, Jahan T, Sondak VK, Strawderman M, LeCarpentier G, Merajver SD, 2000. \"Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study\". <i>Clin Cancer Res</i> <b>6</b>: 1-10.</span>\n</li>\n<li id=\"cite_note-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-5\">^</a></b></span> <span class=\"reference-text\">Gartner EM, Griffith KA, Pan Q, Brewer GJ, Henja GF, Merajver SD, Zalupski MM, 2009. \"A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer\". <i>Invest New Drugs</i> <b>27</b>: 159-165.</span>\n</li>\n<li id=\"cite_note-6\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-6\">^</a></b></span> <span class=\"reference-text\">Henry NL, Dunn R, Merjaver S, Pan Q, Pienta KJ, Brewer G, Smith DC, 2006. \"Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer\". <i>Oncology</i> <b>71</b>: 168-175.</span>\n</li>\n<li id=\"cite_note-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-7\">^</a></b></span> <span class=\"reference-text\">Jain S, Cohen J, Ward MM, Kornhauser N, Chuang E, Cigler T, Moore A, Donovan D, Lam C, Cobham MV, Schneider S, Hurtado Rua SM, Benkert S, Mathijsen Greenwood C, Zelkowitz R, Warren JD, Lane ME, Mittal V, Rafii S, Vahdat LT, 2013. \"Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse\". <i>Annals of Oncology</i>.</span>\n</li>\n<li id=\"cite_note-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-8\">^</a></b></span> <span class=\"reference-text\">Lin J, Zahurak M, Beer TM, Ryan CJ, Wilding G, Mathew P, Morris M, Callahan JA, Gordon G, Reich SD, Carducci MA, Antonarakis ES, 2011. \"A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naive prostate cancer\". <i>Urologic oncology</i>. <b>31(5)</b>:581-8.</span>\n</li>\n<li id=\"cite_note-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-9\">^</a></b></span> <span class=\"reference-text\">Lowndes SA, Adams A, Timms A, Fisher N, Smythe J, Watt SM, Joel S, Donate F, Hayward C, Reich S, Middleton M, Mazar A, Harris AL, 2008. \"Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors\". <i>Clin Cancer Res</i> <b>14</b>: 7526-7534.</span>\n</li>\n<li id=\"cite_note-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-10\">^</a></b></span> <span class=\"reference-text\">Pass HI, Brewer GJ, Dick R, Carbone M, Merajver S, 2008. \"A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results\". <i>Ann Thorac Surg</i> <b>86</b>: 383-389; discussion 390.</span>\n</li>\n<li id=\"cite_note-11\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-11\">^</a></b></span> <span class=\"reference-text\">Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, Brewer GJ, Merajver SD, 2003. \"Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer\". <i>Clin Cancer Res</i> <b>9</b>: 1666-1672.</span>\n</li>\n<li id=\"cite_note-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-12\">^</a></b></span> <span class=\"reference-text\">Schneider BJ, Lee JS, Hayman JA, Chang AC, Orringer MB, Pickens A, Pan CC, Merajver SD, Urba SG, 2012. \"Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer\". <i>Invest New Drugs</i>.</span>\n</li>\n<li id=\"cite_note-13\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-13\">^</a></b></span> <span class=\"reference-text\">Roberts EA, Schilsky L, 2008. \"Diagnosis and Treatment of Wilson Disease: An Update.\" \"AASDL Clinical Practice Guidelines in Wilson Disease.\" <i>Hepatology</i> <b>47,6</b>:2089-2111.</span>\n</li>\n<li id=\"cite_note-14\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-14\">^</a></b></span> <span class=\"reference-text\">Brewer GJ, Askari F, Dick RB, Sitterly J, Fink JK, Carlson M, Kluin KJ, Lorincz MT, 2009. \"Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine\". <i><a href=\"/wiki/Translational_Research_(journal)\" title=\"Translational Research (journal)\">Translational Research</a></i> <b>154</b>: 70-77.</span>\n</li>\n<li id=\"cite_note-15\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-15\">^</a></b></span> <span class=\"reference-text\">Brewer GJ, Askari F, Lorincz, MT, Carlson M, Schilsky M, Kluin KJ, Hedera P, Moretti P, Fink JK, Tankanow R, Dick RB, Sitterly J, 2006. \"Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease\". <i>Arch Neurol</i> <b>63</b>: 521-527.</span>\n</li>\n<li id=\"cite_note-16\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-16\">^</a></b></span> <span class=\"reference-text\">Brewer GJ, Hedera P, Kluin KJ, Carlson M, Askari F, Dick RB, Sitterly J, Fink JK, 2003. \"Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy\". <i>Arch Neurol</i> <b>60</b>: 379-385.</span>\n</li>\n<li id=\"cite_note-17\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-17\">^</a></b></span> <span class=\"reference-text\">Askari F, Innis D, Dick RB, Hou G, Marrero J, Greenson J, Brewer GJ, 2010. \"Treatment of primary biliary cirrhosis with tetrathiomolybdate: results of a double-blind trial.\" <i><a href=\"/wiki/Translational_Research_(journal)\" title=\"Translational Research (journal)\">Translational Research</a></i> <b>155</b>: 123-130.</span>\n</li>\n<li id=\"cite_note-18\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-18\">^</a></b></span> <span class=\"reference-text\">Vine AK, Brewer GJ, 2002. \"Tetrathiomolybdate as an antiangiogenesis therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration\". <i>Trans Am Ophthalmol Soc</i> <b>100</b>: 73-76; discussion 76-77.</span>\n</li>\n<li id=\"cite_note-19\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-19\">^</a></b></span> <span class=\"reference-text\">\"Wilson Therapeutics\" <i>Life Science Sweden</i>. April 17, 2014.</span>\n</li>\n<li id=\"cite_note-20\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-20\">^</a></b></span> <span class=\"reference-text\">\"Wilson Therapeutics Raises $40M Series B to Rid Body of Excess Copper.\" <i>Private Equity and Venture Capital Dow Jones</i>. April 16, 2014.</span>\n</li>\n<li id=\"cite_note-21\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-21\">^</a></b></span> <span class=\"reference-text\">\"Venture Capitalists support new approach to pain.\" <i>MedNous Opportunities in European Medical Innovation</i>. <b>8(5)</b>:19. May 2014.</span>\n</li>\n<li id=\"cite_note-22\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-22\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external autonumber\" href=\"http://www.di.se/artiklar/2016/4/29/wilson-therapeutics-vill-noteras-pa-stockholmsborsen\">[2]</a></span>\n</li>\n<li id=\"cite_note-23\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-23\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external autonumber\" href=\"http://www.nasdaqomx.com/newsroom/pressreleases/pressrelease?messageId=1459074&amp;displayLanguage=en\">[3]</a></span>\n</li>\n</ol></div>\n\n<!-- \nNewPP limit report\nParsed by mw1272\nCached time: 20180909121815\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.128 seconds\nReal time usage: 0.178 seconds\nPreprocessor visited node count: 994/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 7447/2097152 bytes\nTemplate argument size: 1049/2097152 bytes\nHighest expansion depth: 11/40\nExpensive parser function count: 1/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 10710/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.034/10.000 seconds\nLua memory usage: 1.37 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  148.065      1 -total\n 47.24%   69.945      1 Template:Infobox_company\n 37.51%   55.537      1 Template:Infobox\n 33.86%   50.142      1 Template:Fact\n 29.05%   43.014      1 Template:Fix\n 19.38%   28.701      2 Template:Category_handler\n 10.31%   15.265      1 Template:Reflist\n  6.80%   10.063      1 Template:Br_separated_entries\n  6.56%    9.712      1 Template:Delink\n  2.07%    3.067      1 Template:Fix/category\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:43152107-0!canonical and timestamp 20180909121815 and revision id 827550748\n -->\n</div>"},"langlinks":[],"categories":[{"sortkey":"","hidden":"","*":"All_articles_with_unsourced_statements"},{"sortkey":"","hidden":"","*":"Articles_with_unsourced_statements_from_May_2017"},{"sortkey":"","*":"Pharmaceutical_companies_of_Sweden"},{"sortkey":"","*":"Rare_diseases"},{"sortkey":"","*":"Genetic_diseases_and_disorders"},{"sortkey":"","*":"Orphan_drug_companies"}],"links":[{"ns":14,"exists":"","*":"Category:Articles with unsourced statements from May 2017"},{"ns":0,"exists":"","*":"Bis-choline tetrathiomolybdate"},{"ns":0,"exists":"","*":"Decuprate"},{"ns":0,"exists":"","*":"Genetic disorder"},{"ns":0,"exists":"","*":"HealthCap"},{"ns":0,"exists":"","*":"List of business entities"},{"ns":0,"exists":"","*":"Nasdaq Stockholm"},{"ns":0,"exists":"","*":"Oncology"},{"ns":0,"exists":"","*":"Orphan drug"},{"ns":0,"exists":"","*":"Ticker symbol"},{"ns":0,"exists":"","*":"Translational Research (journal)"},{"ns":0,"exists":"","*":"Wilson's disease"},{"ns":4,"exists":"","*":"Wikipedia:Citation needed"}],"templates":[{"ns":10,"exists":"","*":"Template:Infobox company"},{"ns":10,"exists":"","*":"Template:Infobox"},{"ns":10,"exists":"","*":"Template:Longitem"},{"ns":10,"exists":"","*":"Template:Br separated entries"},{"ns":10,"exists":"","*":"Template:Comma separated entries"},{"ns":10,"exists":"","*":"Template:Template other"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:Fact"},{"ns":10,"exists":"","*":"Template:Citation needed"},{"ns":10,"exists":"","*":"Template:Fix"},{"ns":10,"exists":"","*":"Template:Category handler"},{"ns":10,"exists":"","*":"Template:Fix/category"},{"ns":10,"exists":"","*":"Template:Delink"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Column-width"},{"ns":828,"exists":"","*":"Module:Infobox"},{"ns":828,"exists":"","*":"Module:Navbar"},{"ns":828,"exists":"","*":"Module:InfoboxImage"},{"ns":828,"exists":"","*":"Module:Separated entries"},{"ns":828,"exists":"","*":"Module:TableTools"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"},{"ns":828,"exists":"","*":"Module:Unsubst"},{"ns":828,"exists":"","*":"Module:Category handler"},{"ns":828,"exists":"","*":"Module:Yesno"},{"ns":828,"exists":"","*":"Module:Category handler/data"},{"ns":828,"exists":"","*":"Module:Category handler/config"},{"ns":828,"exists":"","*":"Module:Category handler/shared"},{"ns":828,"exists":"","*":"Module:Category handler/blacklist"},{"ns":828,"exists":"","*":"Module:Namespace detect/data"},{"ns":828,"exists":"","*":"Module:Namespace detect/config"},{"ns":828,"exists":"","*":"Module:Delink"},{"ns":828,"exists":"","*":"Module:No globals"}],"images":["Wilson_Therapeutics_Company_Logo.png"],"externallinks":["http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=346511","http://www.di.se/artiklar/2016/4/29/wilson-therapeutics-vill-noteras-pa-stockholmsborsen","http://www.nasdaqomx.com/newsroom/pressreleases/pressrelease?messageId=1459074&displayLanguage=en","http://www.wilsontherapeutics.com"],"sections":[{"toclevel":1,"level":"2","line":"Clinical trials","number":"1","index":"1","fromtitle":"Wilson_Therapeutics","byteoffset":3032,"anchor":"Clinical_trials"},{"toclevel":1,"level":"2","line":"History","number":"2","index":"2","fromtitle":"Wilson_Therapeutics","byteoffset":7996,"anchor":"History"},{"toclevel":1,"level":"2","line":"References","number":"3","index":"3","fromtitle":"Wilson_Therapeutics","byteoffset":9070,"anchor":"References"}],"parsewarnings":[],"displaytitle":"Wilson Therapeutics","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q18395077"}]}}